Cipla

CIPLA.NS

Mumbai, India· Est. 1935

cipla.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CIPLA.NS · Stock Price

INR 1,364.40-122.40 (-8.23%)

Market Cap: $11.7B

Historical price data

Market Cap: $11.7BPipeline: 12 drugs (7 Phase 3)Patents: 20Founded: 1935Employees: 35,000-40,000HQ: Mumbai, India

Sector Ranking#12 in Small Molecule Drugs #5 in Drug Delivery & Formulation

Overview

Cipla's mission is to ensure that no patient is denied access to high-quality, affordable medicine. A global leader with a market valuation exceeding $988 billion, the company has achieved this through pioneering complex generics, strategic international expansion, and a robust manufacturing footprint. Its core strategy leverages deep R&D in respiratory and oncology, vertical integration via API production, and a diversified geographic presence to drive sustainable growth and market leadership.

RespiratoryOncologyImmunologyAnti-infectivesCardiovascularCNS

Technology Platform

Cipla's technology platform is anchored in complex generic formulations (especially inhalation devices and sterile injectables), advanced drug delivery systems, and a growing capability in biosimilar development and manufacturing.

Pipeline

12 drugs in pipeline7 in Phase 3

Drug	Indication	Stage
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triom...	HIV	Approved
Insulin Lispro-aabc + Insulin Glargine	Diabetes Mellitus, Type 2	Approved
CBT124 + EU-sourced Avastin® + Carboplatin + Paclitaxel	Non-Small Cell Lung Carcinoma	Phase 3
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) ...	Bronchial Asthma	Phase 3
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + ...	Asthma	Phase 3

FDA Approved Drugs

LIRAGLUTIDEANDAFeb 24, 2026

LIRAGLUTIDEANDAJan 14, 2026

TICAGRELORANDAOct 28, 2025

Opportunities

Significant opportunities exist in the growing global biosimilars market, expanding access to complex generics in the US and Europe, and deepening penetration in under-served emerging markets where healthcare infrastructure is improving.

Digital health integration presents a new frontier for patient engagement.

Risk Factors

Key risks include intense pricing pressure in generics, regulatory compliance challenges across multiple geographies, potential pipeline setbacks in complex drug development, and geopolitical volatility affecting emerging market operations.

Competitive Landscape

Cipla competes with large Indian generics firms (Sun Pharma, Dr. Reddy's), global generics leaders (Teva, Viatris), and originator companies in biosimilars. Its competitive edge lies in its specialized respiratory franchise, vertical integration with API manufacturing, and strong dual presence in both emerging and developed markets.